<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T06:26:26Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/10095" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/10095</identifier><datestamp>2025-10-24T10:27:06Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-10-24T10:27:06Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_10095">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/10095</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer</dc:title>
               <dc:creator>Benavente, Sergi</dc:creator>
               <dc:subject>Cap - Càncer - Immunoteràpia</dc:subject>
               <dc:subject>Coll - Càncer - Immunoteràpia</dc:subject>
               <dc:subject>DISEASES::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy</dc:subject>
               <dc:subject>PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment</dc:subject>
               <dc:subject>ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de cabeza y cuello</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia</dc:subject>
               <dc:subject>FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral</dc:subject>
               <dc:description>Tumor microenvironments; Head and neck cancer; Radiotherapy</dc:description>
               <dc:description>Microambientes tumorales; Cáncer de cabeza y cuello; Radioterapia</dc:description>
               <dc:description>Microambients tumorals; Càncer de cap i coll; Radioteràpia</dc:description>
               <dc:description>Despite intensive efforts and refined techniques, overall survival in HPV-negative head and neck cancer remains poor. Robust immune priming is required to elicit a strong and durable antitumor immune response in immunologically cold and excluded tumors like HPV-negative head and neck cancer. This review highlights how the tumor microenvironment could be affected by different immune and stromal cell types, weighs the need to integrate metabolic regulation of the tumor microenvironment into cancer treatment strategies and summarizes the emerging clinical applicability of personalized immunotherapeutic strategies in HPV-negative head and neck cancer.</dc:description>
               <dc:date>2025-10-24T10:27:06Z</dc:date>
               <dc:date>2025-10-24T10:27:06Z</dc:date>
               <dc:date>2023-08-17T11:50:51Z</dc:date>
               <dc:date>2023-08-17T11:50:51Z</dc:date>
               <dc:date>2023-05-30</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/10095</dc:identifier>
               <dc:relation>Cancer Drug Resistance;6</dc:relation>
               <dc:relation>http://dx.doi.org/10.20517/cdr.2022.141</dc:relation>
               <dc:rights>Attribution 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>OAE Publishing</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>